<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5125">
  <stage>Registered</stage>
  <submitdate>10/06/2015</submitdate>
  <approvaldate>10/06/2015</approvaldate>
  <nctid>NCT02470884</nctid>
  <trial_identification>
    <studytitle>FAST Feasibility Study</studytitle>
    <scientifictitle>Fully Absorbable Scaffold Feasibility Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>S2327</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Boston Scientific Fully Absorbable Scaffold

Experimental: FAST - Subjects treated with the Boston Scientific Fully Absorbable Scaffold


Treatment: devices: Boston Scientific Fully Absorbable Scaffold
Attempt to implant the Boston Scientific Fully Absorbable Scaffold.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical Procedural Success - Percent diameter stenosis =30% and no in-hospital MACE (Death, MI or TLR)</outcome>
      <timepoint>In-hospital (through discharge or 7 days from the index procedure, whichever is sooner)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>In-scaffold late loss - angiographic endpoint</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject must be at least 18 years of age

          -  Subject (or legal guardian) understands the study requirements and the treatment
             procedures and provides written informed consent before any study-specific tests or
             procedures are performed

          -  Subject is eligible for percutaneous coronary intervention (PCI) and is an acceptable
             candidate for coronary artery bypass grafting (CABG)

          -  Subject has either:

        Symptomatic coronary artery disease with one of the following: stenosis &gt; 70%, abnormal
        fractional flow reserve (FFR), abnormal stress or imaging stress test, or elevated
        biomarkers prior to the procedure or Documented silent ischemia based on one of the
        following: abnormal fractional flow reserve (FFR), abnormal stress or imaging stress test,
        or elevated biomarkers prior to the procedure

          -  Subject is willing to comply with all protocol-required follow-up evaluation

          -  Target lesion must be &lt;12 mm in length with reference vessel diameter &gt;2.75 mm and
             &lt;3.25 mm

          -  Target lesion must have visually estimated stenosis &gt;50% and &lt;100% with thrombolysis
             in Myocardial Infarction (TIMI) flow &gt;1

          -  The target lesion must be successfully predilated Note: Successful predilatation
             refers to dilatation with a balloon catheter of appropriate length and diameter with
             =30% residual stenosis and no dissection greater than National Heart, Lung, Blood
             Institute (NHLBI) type C.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
             acute MI

          -  Subjects with unstable angina or recent MI (clinically diagnosed within the past 2
             weeks) must have cardiac troponin (cTn) documented prior to the procedure and are
             excluded if cTn is &gt; 5x ULN

          -  Subject has cardiogenic shock, hemodynamic instability requiring inotropic or
             mechanical circulatory support, intractable ventricular arrhythmias, or ongoing
             intractable angina

          -  Non-target vessel or side branch has been treated with any type of PCI (e.g., balloon
             angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to the index
             procedure

          -  Target vessel has been treated with any type of PCI (e.g., balloon angioplasty, stent,
             cutting balloon, atherectomy) within 1 year prior to the index procedure

          -  Planned PCI or CABG after the index procedure

          -  Subject has a known allergy to contrast that cannot be adequately premedicated or to
             the study scaffold system or protocol-required concomitant medications (e.g.,
             everolimus or structurally related compounds, polymer or individual components, all
             P2Y12 inhibitors, or aspirin)

          -  Subject has received an organ transplant or is on a waiting list for an organ
             transplant

          -  Subject is receiving or scheduled to receive chemotherapy within 30 days before or
             after the index procedure

          -  Subject has a known condition(s) of the following (as assessed prior to the index
             procedure):

               -  Other serious medical illness (e.g., cancer, congestive heart failure) that may
                  reduce life expectancy to less than 24 months

               -  Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)

               -  Planned procedure that may cause non-compliance with the protocol or confound
                  data interpretation

          -  Subject previously treated at any time with intravascular brachytherapy

          -  Subject is receiving chronic (&gt; 72 hours) anticoagulation therapy (i.e., heparin,
             coumadin) for indications other than acute coronary syndrome

          -  Subject has a platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3

          -  Subject has a white blood cell (WBC) count &lt;3,000 cells/mm3

          -  Subject has documented or suspected liver disease that is clinically significant,
             including laboratory evidence of active hepatitis

          -  Subject is on dialysis or has baseline serum creatinine level &gt;2.0mg/dL (177Âµmol/L)

          -  Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Subject has had a history of cerebrovascular accident (CVA) or transient ischemic
             attack (TIA) within the past 6 months

          -  Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding

          -  Subject has signs or symptoms of active heart failure (i.e., is NYHA class IV) at the
             time of the index procedure

          -  Subject is participating in another investigational drug or device clinical study that
             has not reached its primary endpoint

          -  Subject intends to participate in another investigational drug or device clinical
             study within 12 months after the index procedure

          -  Subject is a woman of child-bearing potential with known intention to procreate within
             12 months after the index procedure. (Women of child-bearing potential who are
             sexually active must agree to use a reliable method of contraception from the time of
             screening through 12 months after the index procedure)

          -  Subject is a woman who is pregnant or nursing (A pregnancy test must be performed
             within 7 days prior to the index procedure in women of child-bearing potential)

          -  Planned treatment of more than 1 target lesion and 1 non-target lesion (see below
             "Multiple Interventions During Index Procedure")

          -  Planned treatment of the target lesion with more than 1 scaffold

          -  Target lesion is located in the left main

          -  Target lesion is located within 3mm of the origin of the left anterior descending
             (LAD) coronary artery, left circumflex (LCX) coronary artery or right coronary artery
             (RCA)

          -  Target lesion is located within a saphenous vein graft or arterial graft or will be
             accessed via a saphenous vein graft or an arterial graft

          -  Target lesion involves a side branch &gt;2.0mm in diameter

          -  Target lesion involves a clinically significant side branch &lt;2.0 mm in diameter that
             has a clinically significant stenosis at the ostium.

          -  Target lesion and/or target vessel proximal to the target lesion is moderately to
             severely calcified

          -  Excessive tortuosity or extreme angulation proximal to or within the target lesion

          -  Target lesion is restenotic from a previous stent implantation

          -  Thrombus, or possible thrombus, present in the target vessel

          -  Non-target lesion to be treated during the index procedure meets any of the following
             criteria:

               -  Located within the target vessel

               -  Located within a bypass graft (venous or arterial)

               -  Left main location

               -  Chronic total occlusion

               -  Involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with
                  more than 1 stent)

               -  Restenotic from previous intervention

          -  Subject has unprotected left main coronary artery disease (&gt;50% diameter stenosis)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>15/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>33</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/03/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>St. Vincent's Hospital - Fitzroy</hospital>
    <hospital>Peninsula Health - Frankston</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <postcode>4032 - Chermside</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3168 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A prospective multi-center, single arm feasibility study to assess the safety and performance
      of the Boston Scientific Fully Absorbable Scaffold.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02470884</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sujth Seneviratne, MBBS</name>
      <address>MonashHeart, Southern Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>